GERON CORP Long-Term Debt
GERON CORP (GERN) had Long-Term Debt of $120.13 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Noncurrent
us-gaap:LongTermDebtNoncurrent · last filed 2026-08-05
- 2026-06-30: Long-term Debt, Excluding Current Maturities $120.13M.
- 2026-03-31: Long-term Debt, Excluding Current Maturities $119.83M.
- 2025-12-31: Long-term Debt, Excluding Current Maturities $119.55M.
- 2025-09-30: Long-term Debt, Excluding Current Maturities $119.26M.
| Period end | Long-term Debt, Excluding Current Maturities |
|---|---|
| 2026-06-30 | $120.13M 10-Q · filed 2026-08-05 |
| 2026-03-31 | $119.83M 10-Q · filed 2026-05-06 |
| 2025-12-31 | $119.55M 10-Q · filed 2026-08-05 |
| 2025-09-30 | $119.26M 10-Q · filed 2025-11-07 |
| 2025-06-30 | $118.99M 10-Q · filed 2025-08-06 |
| 2025-03-31 | $118.73M 10-Q · filed 2025-05-07 |
| 2024-12-31 | $118.48M 10-K · filed 2026-03-02 |
| 2024-09-30 | $12.28M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $36.52M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $11.22M 10-Q · filed 2024-05-02 |
| 2023-12-31 | $35.05M 10-K · filed 2025-02-27 |
| 2023-09-30 | $29.84M 10-Q · filed 2023-11-02 |
| 2023-06-30 | $40.80M 10-Q · filed 2023-08-03 |
| 2023-03-31 | $51.40M 10-Q · filed 2023-05-11 |
| 2022-12-31 | $30.21M 10-K · filed 2024-02-28 |
| 2022-09-30 | $37.80M 10-Q · filed 2022-11-07 |
| 2022-06-30 | $45.26M 10-Q · filed 2022-08-11 |
| 2022-03-31 | $50.18M 10-Q · filed 2022-05-09 |
| 2021-12-31 | $49.83M 10-K · filed 2023-03-16 |
| 2021-09-30 | $34.67M 10-Q · filed 2021-11-09 |
| 2021-06-30 | $34.42M 10-Q · filed 2021-08-16 |
| 2021-03-31 | $24.22M 10-Q · filed 2021-05-10 |
| 2020-12-31 | $24.04M 10-K · filed 2022-03-10 |
| 2020-09-30 | $23.89M 10-Q · filed 2020-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B |